Bipolar depression: pharmacotherapy and related therapeutic strategies (Q34052825)

30 July 2017

1 reference

title

Bipolar depression: pharmacotherapy and related therapeutic strategies (English)

1 reference

30 July 2017

0 references

1 reference

Thase ME

1

1 reference

PubMed ID

11018227

30 July 2017

Sachs GS

series ordinal

2

1 reference

PubMed ID

11018227

30 July 2017

language of work or name

English

0 references

publication date

1 September 2000

1 reference

30 July 2017

Biological Psychiatry

1 reference

30 July 2017

48

1 reference

30 July 2017

6

1 reference

30 July 2017

558-572

1 reference

The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV.

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Switching From 'Unipolar' to Bipolar II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Gabapentin in the acute treatment of refractory bipolar disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Antidepressant-induced mania and cycle acceleration: a controversy revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Efficacy of moclobemide in different patient groups: a meta-analysis of studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

"A two-illness model of bipolar disorder"--by RT Joffe, LT Young, and GM MacQueen: a commentary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

The efficacy of lamotrigine in rapid cycling and non–rapid cycling patients with bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Relation of serum valproate concentration to response in mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Somatic symptoms in primary affective disorder. Presence and relationship to the classification of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

The significance of past mania or hypomania in the course and outcome of major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Rapid cycling manic depressive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Gabapentin treatment of mood disorders: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Long-term risperidone treatment in bipolar disorder: 6-month follow up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Bupropion in depression. II. The role of metabolites in clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Bupropion slow-release response in depression: diagnosis and biochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Lithium Response in Unipolar Versus Bipolar Depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Evidence of the dual mechanisms of action of venlafaxine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Treatment of previously intractable depressions with tranylcypromine and lithium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

A double-blind study of tranylcypromine treatment of major anergic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Tranylcypromine versus imipramine in anergic bipolar depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

A two-illness model of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Agitated depression as a mixed state and the problem of melancholia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Safety review of adult clinical trial experience with lamotrigine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Are there any differences between bipolar and unipolar melancholia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Repetitive transcranial magnetic stimulation: perspectives for application in the treatment of bipolar and unipolar disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Newer antidepressants and the cytochrome P450 system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Treatment of social phobia with gabapentin: a placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

GABA and mood disorders: a brief review and hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Clorgyline. A new treatment for patients with refractory rapid-cycling disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Continuation drug therapy for major depressive episodes: how long should it be maintained?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Medication resistance and clinical response to electroconvulsive therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Treatment-resistant bipolar depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Bipolar disorder therapeutics: maintenance treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Impact of substance abuse on the course and treatment of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Treatment of bipolar depression: a survey of Canadian psychiatrists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Electroconvulsive treatment compared with lithium in the management of manic states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Treatment of acute bipolar depression: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Depression during mania. Treatment response to lithium or divalproex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

MAOIs in the Contemporary Treatment of Depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Is delusional depression related to bipolar disorder?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

Acute treatment of bipolar depression with gabapentin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900980-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(00)00980-X

1 reference

30 July 2017

1 reference

PubMed ID

11018227